La chaîne d'options affiche les données clés des options sur actions de Celularity à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Celularity..

Celularity (NASDAQ:CELU) Stock, Chaîne d'Options

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.53) by 5.66 percent. This is a 45.65 percent increase over losses of $(0.92) per share from the same period last year.

Earnings

Earnings Beats

News

VTYX

Ventyx Biosciences Q3 EPS $(0.50) Beats $(0.53) Estimate

AvePoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. The company reported quarterly sales of $88.804 million which beat the analyst consensus estimate of $83.386 million by 6.50 percent. This is a 22.05 percent increase over sales of $72.760 million the same period last year.

AVPT

AvePoint Q3 2024 GAAP EPS $0.01 Beats $(0.01) Estimate, Sales $88.804M Beat $83.386M Estimate

Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) sees Q4 sales of $237.000 million-247.000 million vs $238.51 million estimate.

Guidance

RDFN

Redfin Sees Q4 Sales $237.000M-247.000M vs $238.51M Est

Buybacks

Universal Approves $100M Repurchase Program

Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.40) by 2.5 percent.

NKTX

Nkarta Q3 2024 GAAP EPS $(0.39) Beats $(0.40) Estimate

Orion Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONL#NYSE">ONL</a>) raises FY2024 FFO guidance from $0.97-1.01 to $0.99-1.01 vs $1.01 analyst estimate..

Orion Office REIT Raises FY2024 FFO Guidance from $0.97-1.01 to $0.99-1.01 vs $1.01 Est

Pinterest Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) reported financial results for the third quarter after the market close on Thursday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41823874/pinterest-announces-third-quarter-2024-results-delivering-sustained-revenue-and-user-growth">key details from the quarter</a>.
Q3 Earnings: Pinterest reported third-quarter revenue of $898 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a> of $896.35 million. The idea discovery platform company reported third-quarter earnings of four cents per share, missing analyst estimates of seven cents per share, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 18% on a year-over-year basis. Pinterest&#8217;s global monthly active users increased 11% year-over-year to 537 million. Average revenue per user was $1.70 globally and $7.31 in the U.S. and Canada.
&#8220;Our AI investments are driving results by powering better-personalized experiences and greater performance for advertisers, with our lower-funnel ad tools being the fastest-growing part of our business,&#8221; said Bill Ready, CEO of Pinterest.
&#8220;Advertisers are increasingly relying on Pinterest to engage our growing audience who see us as a great place to find inspiration, curate and shop.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">Rivian Q3 Earnings Highlights: Revenue, EPS Miss, CEO Confident In Q4 Gross Profit, R2 Being &#8216;Fundamental Driver&#8217; Of Growth</a>
Outlook: Pinterest expects fourth-quarter revenue to be in the range of $1.125 billion to $1.145 billion versus estimates of $1.14 billion. The company expects fourth-quarter operating expenses to be in the range of $495 million to $510 million.
Management will hold a conference call to further discuss these results at 4:30 p.m. ET.
PINS Price Action: <a href="https://www.benzinga.com/quote/PINS" target="_blank" rel="noreferrer noopener">Pinterest shares</a> were down 12.17% after hours at $29.80 at the time of publication Thursday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></li>
</ul>
Photo: Shutterstock.

Social Media

After-Hours Center

Movers

PINS

Pinterest Q3 Earnings: Revenue Beat, EPS Miss, Soft Guidance, AI Investments Paying Off And More

NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.34) by 20.59 percent. This is a 19.61 percent increase over losses of $(0.51) per share from the same period last year.

Earnings Misses

NXTC

NextCure Q3 EPS $(0.41) Misses $(0.34) Estimate

a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.20) by 85 percent. The company reported quarterly sales of $149.903 million which beat the analyst consensus estimate of $143.053 million by 4.79 percent. This is a 100.00 percent decrease over sales of $140.833 trillion the same period last year.

a.k.a. Brands Holding Q3 2024 Adj. EPS $(0.37) Misses $(0.20) Estimate, Sales $149.903M Beat $143.053M Estimate

WIIM

PACB

Pacific Biosciences shares are trading lower after the company reported worse-than-expected Q3 revenue results.

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) sees Q4 sales of $76.000 million-80.000 million vs $79.31 million estimate.

MLNK

MeridianLink Sees Q4 Sales $76.000M-80.000M vs $79.31M Est

Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) reported quarterly losses of $(1.51) per share which beat the analyst consensus estimate of $(2.02) by 25.25 percent. This is a 54.1 percent increase over losses of $(3.29) per share from the same period last year. The company reported quarterly sales of $6.84 million which missed the analyst consensus estimate of $8.64 million by 20.78 percent.

ASMB

Assembly Biosciences Q3 EPS $(1.51) Beats $(2.02) Estimate, Sales $6.84M Miss $8.64M Estimate

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) narrows FY2024 sales outlook from $312.00 million-318.00 million to $313.00 million-317.00 million.

MeridianLink Narrows FY2024 Sales Guidance to $313.00M-317.00M  VS Est.315.81M

BARK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 200 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $126.111 million which beat the analyst consensus estimate of $122.733 million by 2.75 percent. This is a 2.50 percent increase over sales of $123.036 million the same period last year.

BARK

BARK Q2 2025 Adj. EPS $0.01 Beats $0.00 Estimate, Sales $126.111M Beat $122.733M Estimate

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) narrows FY2024 sales outlook from $300.00 million-315.00 million to $305.00 million-310.00 million.

LPSN

LivePerson Narrows FY2024 Sales Guidance from $300.00M-315.00M to $305.00M-310.00M

Redfin shares are trading lower after the company reported worse-than-expected Q3 financial results.

LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) sees Q4 sales of $65.700 million-70.700 million vs $71.26 million estimate.

LivePerson Sees Q4 Sales $65.700M-70.700M vs $71.26M Est

Offerings

Cousins Properties Announces Public Offering of 6,000,000 Shares of Common Stock

SEZL

Sezzle shares are trading higher after the company reported a year-over-year increase in Q3 financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.

Stantec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STN#NYSE">STN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.25 by 4 percent. The company reported quarterly sales of $1.52 billion which missed the analyst consensus estimate of $1.53 billion by 0.25 percent. This is a 55.26 percent increase over sales of $981.58 million the same period last year.

Stantec Q3 2024 Adj EPS C$1.30 Beats C$1.25 Estimate, Sales C$1.52B Miss C$1.53B Estimate

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

RIVN

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Management

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Markets

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

ImmuCell

MiNK Therapeutics

Longeveron

Lantern Pharma

Lumos Pharma

Marker Therapeutics

NextCure

Ocean Biomedical

SAB Biotherapeutics

Surrozen

vTv Therapeutics Inc. - Class A Common Stock

Comments

Celularity

Celularity (CELU) Options

Celularity (NASDAQ:CELU) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL